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Recommendations present the current management, that may be modified and changed in certain cases, after a thorough 
analysis of a given clinical situation, which in the future may be the basis for their modification and actualization.
SUMMARY OF THE RECOMMENDATIONS
Definitions
Fetal Growth Restriction (FGR)— a synonim for 
intrauterine growth restriction (IUGR)
< 32 weeks — early-onset FGR; > 32 — late onset FGR
Hypotrophy — a term related to a newborn with growth 
restriction
Risk factors
Risk factors of growth restriction should be assessed in 
every woman at the beginning of pregnancy and at each 
following visit (Tab. 1A and 1B). Increased risk of FGR is 
diagnosed if, at least one major or three minor risk factors 
are present. Risk may also be determined using an algorithm 
combining ultrasound, medical history, and serum markers.
Confirming the gestational age 
Each pregnant woman should undergo an ultrasound 
examination between 11–13 + 6 weeks of gestation, during 
which the crown-rump length is measured, and the date of 
delivery is determined. If there is no ultrasound examination 
at this time, the delivery date should be determined on the 
basis of HC and FL measurements in the second trimester 
of pregnancy.
Differential diagnosis
Suspicion of abnormal growth should be followed by 
a detailed work up to determine the potential cause (chro-
mosomal abnormalities, infections, congenital anomalies, 
impaired blood flow in the uterine arteries, changes in the 
placenta).
Growth assessment
The recommended method of calculating the estimated 
fetal weight is the Hadlock equation. AC and HC measure-
ments should be made using an ellipse to cover the outer 
contours of the abdomen and fetal head. Based on avail-
ability and accessibility, PSOGO recommends the use of 
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the Hadlock growth charts until the development and dis-
semination of growth standards for the Polish population. 
Fundal height assessment should be performed in 
low-risk pregnancies starting from the 24th week of gesta-
tion.
Diagnosis and management 
We recommend FGR diagnosis based on ultrasound 
criteria reported in the Delphi consensus. After the diagno-
sis, management is always individualized, and surveillance 
should incorporate all the available tools. Management is 
feasible in an outpatient setting. Hospitalization is indicated 
if FGR is accompanied by:
•	 oligohydramnios
•	 abnormal CTG tracings
•	 abnormal biophysical profile 
•	 vaginal bleeding
•	 reduced or rapid fetal movements 
•	 absent or reversed end diastolic flow in the umbilical 
artery 
•	 CPR < 5 percentile
•	 absent or reversed end diastolic flow in the ductus ve-
nous 
•	 other symptoms of fetal distress
Delivery 
Choice of timing and mode of delivery depends on the 
severity of FGR, accompanying abnormalities in CTG trac-
Table 1A. Major risk factors for fetal growth restriction (adapted from RCOG — 13) 
Maternal
Antiphospholipid syndrome RR 6.2 (2.4–16.0)
Diabetes-related angiopathy OR 6 (1.5–2.3) 
Renal insufficiency AOR 5.3 (2.8–10)
Intense physical activity AOR 3.3 (1.5–7.2)
> 40 years of age OR 3.2 (1.9–5.4)
Cocaine OR 3.2 (2.4–4.3)
Maternal birthweight < 10 centile OR 2.6 (2.3–3.0)
Chronic hypertension ARR 2.5 (2.1–2.9)
Smoking >10 cigarettes/day OR 2.2 (2.0–2.4)
Obstetric history Birth of neonate with birthweight < 10 percentile OR 3.9 (2.1–7.1)
Current pregnancy
Pre-eclampsia AOR 2.7 (1.2–4.3)
Threatened abortion accompanied by menstrual-like bleeding AOR 2.6 (1.2–5.6)
Pregnancy-induced hypertension – severe  RR 2.5 (2.3–2.8)
Hyperechogenic bowel of the fetus in II trimester on ultrasound AOR 2.1 (1.5–2.9)
Paternal Paternal birthweight < 10 percentile OR 3.5 (1.3–10.3)
RR — relative risk; OR — odds ratio; AOR — adjusted odds ratio 
Table 1B. Minor risk factors for FGR (adapted from RCOG — 13) 
Maternal
Primiparity OR 1.9 (1.8–2.0)
Diet low in fruit before pregnancy AOR 1.9 (1.3–2.8)
IVF OR 1.6 (1.3–2.0)
Obesity BMI ≥ 30 RR 1.5 (1.3–1.7)
Maternal age > 35 years OR 1.4 (1.1–1.8)
Underweight BMI < 20 OR 1.2 (1.1–1.3)
Overweight BMI 25–29.9 RR 1.2 (1.1–1.3)
Obstetric history
Mild pre-eclampsia AOR 1.3 (1.2–1.4)
Time between pregnancies < 6 months AOR 1.3 (1.9–1.3)
Time between pregnancies ≥ 60 months AOR 1.3 (1.2–1.4)
Current pregnancy
Caffeine consumption ≥ 300 mg/daily in the III trimester OR 1.9 (1.3-2.8)
Pregnancy-induced hypertension – mild RR 1.3 (1.3–1.4)
RR — relative risk; OR — odds ratio; AOR — adjusted odds ratio; IVF — in vitro fertilisation; BMI — body mass index 
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ings and ultrasound assessment. In the absence of previous 
indications, delivery is recommended not later than week 37.
ABBREVIATIONS AND DEFINITIONS
AC — abdominal circumference 
AEDV — absent end diastolic velocity 
AGA — appropriate for gestational age — fetuses and 
neonates with estimated fetal weight and neonatal weight 
between the 10–90 percentile 
AOR — adjusted odds ratio 
APLS — antiphospholipid syndrome 
ARR — adjusted relative risk 
BMI — body mass index 
BPD — biparietal diameter 
CPR — cerebro-placental ratio 
CRL — crown-rump-length
DV — Ductus Venous 
Early-onset FGR — early onset growth restriction, onset 
before 32 weeks of gestation 
FGR — fetal growth restriction — is the failure of the fetus 
to achieve the programmed birth weight after excluding 
internal factors (chromosomal aberrations, infections, birth 
defects)
FL — femur length 
HC — head circumference 
Hypotrophy - a term related to a newborn born with growth 
restriction
IUGR — intrauterine growth restriction —synonym of FGR
Late-onset FGR — late onset fetal growth restriction, onset 
after 32 weeks of gestation 
LGA — large for gestational age — fetuses and neonates 
with estimated fetal weight and neonatal weight above 
the 90 centile 
MCA — middle cerebral artery 
OR — odds ratio 
PlGF — placental growth factor 
REDV — reverse end diastolic velocity 
RR — relative risk 
SGA — small-for-gestational-age — fetuses with estimated 
weight (EFW) on ultrasound between the 3rd and 10th per-
centile for gestational age without signs of growth failure 
or newborns with birth weight below the 10th percentile
TORCH —Toxoplasmosis, Rubella, Cytomegalovirus, Herpes 
simplex 
UA — umbilical artery 
UtA — uterine artery 
ARSA — aberrant right subclavian artery 
AIM
The aim of these recommendations is to present FGR 
management principles based on currently available sci-
entific evidence and clinical experience.
INTRODUCTION
Fetal Growth Restriction (FGR) is a clinical situation in which 
the fetus does not reach its programmed birth weight [1]. 
Currently, there are two types of fetal growth restriction. 
Early-onset FGR before 32 weeks of gestation. Early FGR often 
coexists with maternal hypertension or connective tissue 
disease [2]. In the TRUFFLE study, pre-eclampsia was found 
in 75% of pregnancies included in the study [3]. Early FGR is 
an indication to refer the patient to a higher reference level 
and is primarily a challenge in terms of planning appropriate 
management. The natural course of the disease is relatively 
well understood. The GRIT and TRUFFLE studies analyzed the 
effectiveness of various diagnostic and therapeutic regimens 
and their impact on the outcomes of perinatal care (both 
early and late) [3–5]. According to experts, much more con-
troversy exists around late FGR, which is defined as growth 
restriction that occurs after 32 weeks of gestation. In these 
cases, the primary problem is diagnosis in low-risk pregnan-
cies, as in many countries, third trimester ultrasound exami-
nation in this group of women is not recommended (Tab. 2). 
FGR detection in low-risk pregnancies in many countries 
does not exceed 15% [2, 6, 7]. In Poland, it is currently recom-
mended to perform an ultrasound scan in the third trimester 
Table 2. Comparison of early vs late fetal growth restriction
Early FGR Late FGR
Main problem Management Diagnosis
Placental changes  > 30% < 30%
Cardiovascular reaction to hypoxia Adaptation No adaptation 
Tolerance of hypoxia High Natural history of disease established 
Low
Natural history of disease not established
Perinatal mortality High, especially < 26 weeks of pregnancy Low
Perinatal morbidity High, especially < 26 weeks of gestation Increased risk of perinatal complications. Risk of neonatal, childhood and adult morbidity unknown. 
FGR — fetal growth restriction
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between 28–32 weeks of pregnancy and at term [8, 9]. In 
Poland, despite routine performance of the third trimester 
ultrasound, this detection rate is not much higher [10]. One 
of the greatest challenges of modern perinatology is the 
prevention of intrauterine deaths [11]. The experience from 
Great Britain shows that the identification of women with 
an increased risk of growth failure, staff training, the introduc-
tion of diagnostic and therapeutic recommendations and 
guidelines gives a chance to reduce perinatal mortality [12].
Risk factors
Risk factors for growth restriction should be assessed in 
every woman at the beginning of pregnancy and at each 
following visit. FGR risk factors can be classified as major or 
minor depending on the OR, AOR or RR (Tab. 1A and 1B). 
These are risk factors identified on the basis of maternal 
history and the course of current pregnancy. The diagnosis 
of an increased risk of FGR is based on the presence of at 
least one major risk factor or three minor risk factors [13]. 
The screening tests and preventive measures are described 
in detail later in the recommendations. A high risk of FGR in 
the first trimester of pregnancy is an indication to consider 
prophylactic administration of acetylsalicylic acid [14]. 
Pregnant women in Poland rarely admit to smoking. 
It is also difficult to obtain reliable information regarding 
their home exposure to cigarette smoke. According to data 
published for the Polish population, 12% of women continue 
to smoke during pregnancy [15]. Therefore, the risk should 
not be differentiated depending on the number of ciga-
rettes smoked or the environmental exposure. If the patient 
reports that she had stopped smoking in the first trimester, 
we classify it as a major risk factor of FGR.
DIAGNOSIS AND MANAGEMENT
Differential diagnosis
Confirmation of gestational age
The basic criterion for the assessment and diagnosis 
of growth abnormalities is the correct determination of 
the duration of pregnancy. Measuring the CRL between 
8 and 14 weeks of gestation is considered the most accurate 
method of assessing the duration of pregnancy [16]. Cur-
rently, according to the PSOGO recommendations, every 
pregnant woman should undergo an ultrasound examina-
tion between 11–13 + 6 weeks of gestation. In such a case, 
the measurement of the crown-rump length should be 
performed, and the date of delivery be determined on its 
basis. If the duration of pregnancy has been determined 
at that time, it should not be recalculated on the basis of 
subsequent ultrasound examinations. [8]. If data on CRL 
is unavailable, then the HC and FL measurements can be 
used to determine the duration of pregnancy in the second 
trimester [16].
Risk assessment of chromosomal abnormalities
One third of early-onset FGR may coexist with chromo-
somal abnormalities or genetic syndromes [17]. Therefore, 
if FGR is diagnosed before 24 weeks of gestation, the risk 
of chromosome aberrations should be verified. A detailed 
interview regarding what genetic and screening tests have 
been performed so far by the patient is helpful. The medi-
cal documentation should include an annotation whether 
the first trimester screening was performed in accordance 
with the recommendations of PSOGO. If not — it should be 
noted in the documentation whether this was discussed and 
offered to the patient.
The indications for invasive genetic testing in the case 
of FGR are as follows:
•	 Early FGR < 24 weeks 
•	 Major structural defects accompanying FGR
•	 Presence of benign ultrasound markers indicating 
an increased risk of aneuploidy (nuchal fold thickening, 
ventriculomegaly, ARSA, choroid plexus cysts, incorrect 
hand position, septal defects, hyperechogenic bowel, 
shortened humerus, hypoplastic nasal bone < 10 per-
centile).
If the ultrasound examination does not show signs of 
placental insufficiency, and the patient has not had the 
first trimester screening in accordance with the FMF and 
PSOGO standards, or if, despite being at high risk, further 
screening was not performed (free fetal DNA testing), then 
amniocentesis or cordocentesis should be offered. 
Diagnosis of TORCH infections 
FGR suspicion should prompt diagnosis of cytomeg-
aly, toxoplasmosis, rubella and herpes simplex. In Poland, 
routine malaria diagnosis is not recommended, although 
in selected cases, justified by medical history, it may be 
suggested.
Invasive diagnosis to confirm fetal infection should 
be considered individually. Amniocentesis should not be 
performed before 18 weeks of gestation and not earlier 
than 4 weeks after the onset of maternal symptoms. The 
indications for amniocentesis can be both the results of 
serological tests (the presence of specific IgM and IgG an-
tibodies with low avidity of IgG antibodies) [18], as well 
as ultrasound assessment performed by an experienced 
professional or in a dedicated prenatal diagnosis center 
(cerebral, liver microcalcifications, ventriculomegaly, mi-
crocephaly, hepatomegaly, effusion in body cavities, fetal 
edema and placentomegaly) [19].
Anatomy assessment
FGR is an indication for a detailed assessment of fetal 
anatomy. The scope of ultrasound workup depends on the 
gestational age. Estimated fetal weight below the 3rd per-
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centile should include a detailed heart and central nervous 
system evaluation.
Growth assessment 
In a low-risk pregnancy, fetal growth should be assessed 
at week 20–22; 28–32 weeks and after 40 weeks, in accord-
ance with the current standard of perinatal care and the 
PSOGO recommendations [8, 9] (Fig. 1). In a high-risk preg-
nancy, fetal growth should be assessed: at week 20–22; at 
week 26–28; at week 34–38 and week 40 [8] (Fig. 2). In the 
case of FGR diagnosis, the frequency of ultrasound exami-
nations depends on the severity of growth restriction. Fetal 
weight assessment should be made in accordance with the 
Hadlock II methodology, considering the BPD, HC, AC and 
FL measurements. The AC and HC measurements should 
be made using an ellipse and cover the external outline of 
the fetal soft tissues [16].
When assessing the fetal growth, the use of population 
growth charts is recommended [20]. The Z-score can also 
be used, but the percentile method is more readable for 
the recipients [21]. 
An alternative are customized growth charts, which al-
low calculation of the optimal birth weight for a given preg-
nancy, accounting for the mother’s ethnic origin, her height 
and weight before pregnancy and parity [22]. However, 
in the light of previous reports, they do not demonstrate 
a predictive advantage. At the time of delivery, nearly 70% 
of fetuses with weight estimated between the 3rd and 10th 
centile is healthy, and their weight is exclusively constitu-
tional (maternal constitutional conditions, race, fertility, 
BMI) [23]. When assessing the weight of the fetus and its 
centile, it is always worth paying attention to which spe-
cific measured parameter is responsible for the diagnosis 
of FGR. A low fetal weight percentile can sometimes be 
due to, for example, a relatively “shorter” FL measurement 
and may result in an unnecessary implementation of in-
tensive care and invasive measures. At present, there are 
no recommendations to use customized growth charts for 
a given population, although it may be a more appropriate 
diagnostic method in the future [16]. Due to availability, 
PSOGO recommends using the Hadlock II algorithm until 
Polish population standard is developed and disseminated.
Fundal height measurement
The fundal height measurement is an approximate 
method of assessing the stage of pregnancy and the size of 
the fetus. The result is influenced by maternal obesity, parity 
and the obstetrician’s experience. The assessment of fundal 
height can only be used as an indication for ultrasound 
assessment. It can be performed in low-risk pregnancies 
starting from the 24th week of gestation. It involves measur-
ing the distance between the upper edge of the pubic sym-
physis and the floor of the uterus (SF, symphysis-fundal). The 
values and standard deviations of fundal height for a given 
gestational age according to Intergrowth are presented 
in Table 3. FGR is suspected when the SF measurement 
value is lower by 3 or more than 3 centimeters for a given 
gestational age [24]. This is an indication for an ultrasound 
Figure 1. Low-risk pregnancy
Figure 2. High-risk pregnancy
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examination. Fundal height assessment is not indicated in 
patients with pre-pregnancy BMI > 35 and in women with 
large uterine fibroids. 
Delphi Criteria for FGR
In 2016, in order to standardize the diverse nomencla-
ture, a definition of FGR was developed through an inter-
national consensus. This definition applies to fetuses with 
placental growth failure, after excluding congenital abnor-
malities, TORCH infections and chromosomal abnormali-
ties. Fetal growth restriction has been classified into early 
and late onset FGR. The diagnostic criteria are presented 
in Table 4 [25].
As a rough measure, early-onset fetal growth restriction 
begins before 32 weeks of gestation. For diagnosis, one of 
the following parameters must be identified: 
•	 abdominal circumference (AC) measured by ultra-
sound < 3 percentile at a given gestational age,
•	 estimated fetal weight (EFW) measured by ultra-
sound < 3 percentile at a given gestational age,
•	 absent umbilical artery end-diastolic flow (UA AEDV) 
regardless of the estimated fetal weight.
The last of the above-mentioned parameters indicates 
impaired placental flow, which allows to distinguish a group 
of children with potentially impaired growth in the following 
weeks of gestation. Early-onset FGR may also be suspected 
when AC or EFW are lower than the 10th centile at a given 
gestational age, and the umbilical artery (UA) and/or uter-
ine artery (UtA) pulsation index (PI) is greater than the 95th 
centile at a given gestational age. 
Late-onset fetal growth restriction begins after 32 weeks 
of gestation. The diagnosis is made by the occurrence of 
a single parameter:
•	 •	abdominal	circumference	(AC)	as	measured	by	ultra-
sound < 3 centile for a given gestational age
•	 •	estimated	fetal	weight	 (EFW)	<	3	centile	 for	a	given	
gestational age.
The diagnosis of late FGR can also be made when the esti-
mated fetal weight or abdominal circumference is below the 
10th percentile and at least one of the following criteria is met: 
•	 growth inhibition above 2 quartiles (more than 50 cen-
tiles) 
•	 CPR value (quotient of PI in MCA and UA) < 5 percentile 
for a given gestational age
•	 UA PI > 95 percentile for a given gestational age
As in the case of early FGR, the last two of the above-men-
tioned parameters indicate the beginning of possible fetal 
hypoxia, brain-sparing and impaired placental flow, i.e. they 
allow for identification of the group of children with poten-
tially impaired growth in the following weeks of pregnancy.
Early fetal growth restriction
The management of early FGR, the frequency of fetal 
monitoring and the route of delivery depends on severity 
of the disease. In the TRUFFLE study, which compared com-
puter CTG analysis and the assessment of Doppler blood 
flow values in DV in monitoring the well-being of the fetus, 
85% of children in the second year of life had no neurological 
complications, and only 1% had cerebral palsy [4]. The most 
important risk factor for neonatal complications, including 
Table 4. Delphi criteria for diagnosis of early and late fetal growth 
restriction
Early FGR 
Gestational age ≤ 32 weeks
Late FGR
Gestational age > 32 weeks
AC or EFW < 3 percentile or 
UA-AEDF AC or EFW < 3 percentile
or or 2/3 of criteria below
1. AC or EFW < 10 centile and
2. UtA-PI > 95 centile and/or
3. UA-PI > 95 centile
1. AC or EFW < 10 centile
2. AC or EFW drop > 2 quartile 
on the growth chart *
3. CPR < 5 centile or UA-
PI > 95 percentile
*percentiles are not individualized, individual measurements of the fetus 
should be analyzed in each case of a low percentile; FGR — fetal growth 
restriction; AC — abdominal circumference; AEDF — no diastolic flow; CPR 
— cerebroplacental ratio; EFW — Estimated Fetal Weight; PI — pulsation 
indicator; UA — umbilical artery; UtA — uterine artery
Table 3. Fundal height values for a given gestational age (SF) and 







Fundal height —  
≤ 2 standard deviation
(SF — ≤ 2SD) [cm]
24 23.8 ≤ 20.5
25 24.7 ≤ 21.5
26 25.7 ≤ 22.4
27 26.7 ≤ 23.3
28 27.7 ≤ 24.3
29 28.6 ≤ 25.2
30 29.6 ≤ 26.1
31 30.5 ≤ 26.9
32 31.4 ≤ 27.8
33 32.3 ≤ 28.6
34 33.2 ≤ 29.5
35 34.0 ≤ 30.3
36 34.9 ≤ 31.0
37 35.7 ≤ 31.8
38 36.5 ≤ 32.5
39 37.2 ≤ 33.2
40 38.0 ≤ 33.9
41 38.7 ≤ 34.6
42 39.3 ≤ 35.2
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death, was prematurity. The rate of neurological complica-
tions was maintained at similar level regardless of the gesta-
tional age, but it was significantly lower in the study group 
where interventions were based on the blood flow in ductus 
venosus. The highest risk of intrauterine death regarded fe-
tuses with FGR diagnosed before 26 weeks of gestation. Each 
day of intrauterine life between 26–29 weeks of gestation 
increases the chances of proper development by about 2%, 
while between 30–34 only by 1% [26]. There are 4 stages of 
early FGR [27]. Establishing the diagnosis requires a change 
in the supervision method and performing fetal biometry, 
assessment of the amniotic fluid volume and assessment of 
the blood flow in Doppler examination (UtA, UA, MCA and 
DV). The indications for termination of pregnancy consist of 
abnormal values of ultrasound indicators, CTG parameters 
and/or progressing symptoms of pre-eclampsia.
Stage I
Stage I is diagnosed when the estimated fetal weight or 
abdominal circumference are below the 3rd percentile or 
when the fetal weight is between the 3–10th centile, with 
an increased uterine artery pulsatility index (mean PI > 95th 
centile or CPR < 5th centile or MCA < 5th centile). In this case, 
the blood flow should be assessed once a week together 
with an assessment of the amniotic fluid volume, and from 
34 weeks of gestation, a CTG should be performed once 
a week. Fetal weight should not be assessed more frequently 
than every 2 weeks. If the cerebroplacental ratio (CPR) is 
above the 5th centile, there is no need for an assessment of 
the ductus venous (DV) blood flow. If, however, it is below 
the 5th centile, the blood flow in DV should be assessed. 
Normal values are < 95 centile. The most important factor 
in predicting the fetus well-being in CTG is the assessment 
of short-term variability (STV) over a period of 40–60 min-
utes. Amniotic fluid volume can be assessed using both 
the maximum vertical pocket (MVP) and the amniotic fluid 
index (AFI). An incorrect MVP value is < 2 cm, and an incor-
rect AFI index < 5cm.
Stage II 
Stage II is diagnosed in the absence of end-diastolic flow 
in the umbilical cord. It is estimated that the risk of intrauter-
ine death in the absence of end-diastolic flow in the umbili-
cal cord is more than three times increased — OR = 3.59, 
with a 95% CI 2.29–5.62 [28]. This is an indication for urgent 
hospitalization of the patient. It is optimal to implement 
intensive cardiotocographic monitoring. Ultrasound exami-
nation should be performed 2–3 times a week. Blood flow 
in UtA, UA, MCA and DV is evaluated. CPR < 5th percentile 
and MCA < 5th percentile, therefore symptoms of circulatory 
centralization, which are only adaptive symptoms of the 
fetus, are not an indication for termination of pregnancy. 
Persistence of the lack of late-diastolic blood flow is an in-
dication for the administration of steroids and increased 
CTG surveillance. If during observation there is an absent 
a-wave or there is a reversed a-wave in the ductus venosus, 
then it is an indication for an immediate termination of 
pregnancy - the risk of death in this situation is OR = 12.39, 
with a 95% CI 8.49–18.06. In other cases, cardiotocographic 
supervision should be performed daily. With correct CTG, 
pregnancy should be ended after 34 weeks of gestation, 
after a previous steroid therapy.
Stage III 
Stage III is diagnosed when a retrograde wave in the 
umbilical cord or PI in DV > 95 centile are found. In this case, 
the risk of intrauterine death is also high — OR = 7.15, with 
a 95% CI of 5.22–9.81. It is optimal to introduce increased car-
diotocographic monitoring. Ultrasound examination should 
be performed in a hospital setting every 12–24 hours. Preg-
nancy should be ended by caesarean section, after a course 
of steroid therapy in the event of abnormal cardiotoco-
graphic records or persistent flow reversal.
Stage IV
Stage IV is diagnosed when an absence of A wave, re-
verse A wave in DV or incorrect values of the CTG records 
are found. The patient must be hospitalized immediately, be 
under constant cardiotocographic supervision and should 
be given steroids. This is an indication for urgent termination 
of pregnancy by caesarean section.
Regardless of the abnormal values of vascular flow meas-
urements assessed in Doppler examination, an indication 
for termination of pregnancy is reduced to < 3.5 short-term 
variability for > 40 minutes or repeated decelerations in car-
diotocographic tracings [29–31]. The optimal place of hospi-
talization is a tertiary perinatal care center. Hospitalization 
is indicated pending results of cardiotocographic tracings, 
ultrasound assessment, the patient’s condition and the co-
existence of hypertension and pre-eclampsia indicators. The 
diagnosis of pre-eclampsia increases the severity of FGR by 
one level. In case of diagnostic doubts, lack of experience in 
ultrasound evaluation, or lack of appropriate equipment, it is 
recommended to refer the patient at any stage of gestation 
to a reference center or to a perinatal medicine specialist to 
determine further management. 
Hospitalization is indicated in each case of FGR compli-
cated by oligohydramnios (MVP < 2 or AFI < 5), abnormal 
biophysical profile, suspicious CTG recording, vaginal bleed-
ing, reduced fetal movements or lack of end-diastolic flow 
in the umbilical artery.
The assessment of fetal movements after 30 weeks 
of gestation, according to the PSOGO recommendations, 
should take place during the periods of fetus’ highest activity 
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or after main meals (but not within the first hour after eating). 
The correct value is considered to be at least 4 movements 
within an hour or 10 movements within two hours [32].
Supervision of fetal well-being during hospitalization in 
a reference center should be based on recommendations 
to ensure appropriate supervision, consistent with current 
medical knowledge.
The route of delivery should always be chosen indi-
vidually, considering obstetric conditions, risk factors and 
experience of medical personnel, but also an increased 
risk of chronic fetal hypoxia in the event of impaired fetal 
well-being with an indication for caesarean section. After 
the completion of 37 weeks of gestation, in the presence 
of indications for its termination and no contraindications 
to vaginal delivery, it is recommended to induce labor with 
continuous cardiotocographic monitoring. FGR is a con-
traindication to vaginal delivery in case of breech position 
of the fetus. In case of pregnancy with FGR and the need to 
deliver < 32 weeks, it is recommended to administer mag-
nesium sulphate (MgSO4) for neuroprotection of the fetus.
Late fetal growth restriction
In the case of late-onset FGR, the biggest problem is its 
diagnosis and differentiation between the growth-restricted 
fetus and a constitutionally small fetus (SGA). The SGA fetus’ 
growth potential is most likely inherited from its parents. Its 
growth parameters are within 3–10 percentile, but the blood 
flow in the uterine arteries, the umbilical cord, and the mid-
dle cerebral artery is normal. Such fetuses are, in most cases, 
healthy. Termination of pregnancy should occur at the time 
of delivery at the latest, in accordance with the PSOGO 
recommendations on labor induction [33].
Supervision of such fetus requires an evaluation of 
growth dynamics and the blood flow in the vessels every 
2 weeks. In low-risk populations, the number of SGA diag-
nosed at term does not exceed 15%. In studies involving 
populations similar to the Polish one, despite of performing 
the commonly recommended examination between 28 and 
32 weeks of gestation, the rate of such fetuses in low-risk 
pregnancies was 19%, and in high-risk pregnancies 47% 
[10]. Therefore, it is extremely important to select patients 
who require additional ultrasound examination between 
32–40 weeks of gestation. 
In late FGR, we rarely observe an abnormal blood flow 
spectrum in the uterine arteries, but Figueras et al. [27] 
showed that the evaluation of blood flow in these vessels, 
also in pregnancies over 32 weeks, allows for identifica-
tion of fetuses with an increased risk of perinatal complica-
tions. In the DIGITAT study, AEDV was found in only 10% 
of patients, and the mean PI values in the umbilical cord 
ranged from 0.93–0.98 [34]. In late FGR, the most useful is 
the evaluation of CPR or MCA flow, and the values of these 
parameters < 5 percentile allow for identification of fetuses 
in which pregnancy should be terminated earlier [27]. In-
duction of labor at 37 weeks of gestation is indicated for 
fetuses with an estimated weight below the 3rd percentile or 
with an abdominal circumference below the 3rd percentile. 
Early termination of pregnancy should be considered in the 
presence of symptoms of pre-eclampsia, depending on the 
results of cardiotocography and ultrasound examinations. If 
CPR is < 5th percentile or MCA flow is < 5th percentile, the 
ductus venous blood flow should be assessed and the man-
agement like for early FGR should be introduced. The other 
indications for hospitalization, CTG surveillance, delivery 
route, counting fetal movements and assessment of the 
biophysical profile are the same as in early FGR. Regardless of 
whether we are dealing with late FGR or SGA, CTG and USG 
control should be implemented in the event of increased 
blood pressure, vaginal bleeding, uterine contractions and 
reduced fetal movements.
Screening tests and and general prevention
When compiling the management protocols, the au-
thors considered different scenarios depending on whether 
the patient was screened and/or assessed for FGR risk in the 
first trimester of pregnancy. The scheme also assumes a situ-
ation when, despite the existing indications, the pregnant 
woman did not receive or did not start taking acetylsalicylic 
acid. The risk of FGR should be assessed at each stage of 
pregnancy. Scheme I presents the method of risk evaluation 
in the first and second trimesters of pregnancy, taking into 
account the lack of risk assessment based on ultrasound 
and biochemical parameters in the first trimester. In such 
case, it should be done based on the previously described 
risk factors (1A and 1B).
In a single pregnancy, the Polish Society of Gynecologists 
and Obstetricians recommends the use of prenatal screening 
between 11 and 13 + 6 weeks of pregnancy to evaluate the 
risk of early-onset FGR with Doppler evaluation of uterine 
blood flow (UtA), mean arterial pressure (MAP) and deter-
mine the value of placental growth factor (PlGF) in blood. 
In high-risk situations (> 1: 100), it is justified to start the ad-
ministration of 150 mg of acetylsalicylic acid before 16 weeks 
of gestation and continue it until the 36th week [14] (Fig. 3).
According to the PSOGO standards, ultrasound examina-
tion should be performed at 11–14, 20 and 28–32 weeks of 
gestation. In a group at high risk of FGR and/or pre-eclamp-
sia identified on the basis of the first trimester screening, 
a screening between 19–24 weeks of gestation should be 
considered using the patient’s history and UtA PI, MAP, PlGF 
and sFlt-1 evaluation. Ultrasound assessment of growth 
should be performed according to the scheme outlined 
for high-risk pregnancies (High-risk pregnancy manage-
ment scheme).
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However, in low-risk pregnancies, it may be considered 
to evaluate the uterine blood flow in the second and third 
trimesters. In the case of correct biometry and PI UtA> 95th 
percentile, we recommend an additional control of growth 
dynamics between 34-38.
Confirming the high risk of early-onset FGR/pre-eclamp-
sia occurrence (> 1:100) entails an individualized approach 
in the form of every-day blood pressure measurements, 
weekly assessment of proteinuria and periodic evaluation 
of fetal biometry. 
Placenta
Examination of the placenta: description of macroscopic 
changes in medical record documentation and possibly 
a histopathological examination.
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